Profitability
by Company within Biotechnology & Pharmaceuticals Industry
|
Company |
Quarter |
Gross Margin |
Net Margin |
Cash flow Margin |
ROE |
Abcam Plc |
4 Q |
74.79% |
-2.35% |
0% |
- |
Acumen Pharmaceuticals Inc |
3 Q |
- |
- |
- |
-23.86% |
Aceragen Inc |
1 Q |
- |
-885.3% |
-401.86% |
-215.27% |
Achilles Therapeutics Plc |
4 Q |
- |
- |
- |
-36.12% |
Arcellx Inc |
3 Q |
- |
-262.99% |
-1170.81% |
-48.49% |
Acorda Therapeutics Inc |
3 Q |
87.78% |
-32.07% |
26.09% |
-21.45% |
Adaptimmune Therapeutics Plc |
4 Q |
- |
-2622.71% |
- |
-134.69% |
Adma Biologics Inc |
4 Q |
41.62% |
-23.62% |
-30.53% |
-19.51% |
Adaptive Biotechnologies Corporation |
3 Q |
48.98% |
-132.72% |
-54.14% |
-47.64% |
Adverum Biotechnologies Inc |
4 Q |
- |
- |
- |
-98.65% |
Aerie Pharmaceuticals Inc |
3 Q |
80.82% |
-74.25% |
40.55% |
- |
Agenus Inc |
3 Q |
98.75% |
-265.41% |
-147.65% |
- |
Applied Genetic Technologies Corporation |
3 Q |
- |
- |
- |
-192.9% |
Aim Immunotech Inc |
2 Q |
-130% |
-16170% |
- |
-38.93% |
Avalon Globocare Corp |
3 Q |
- |
-448.27% |
-94% |
-55.9% |
Alector Inc |
3 Q |
- |
-488.25% |
-324.72% |
-74.78% |
Aligos Therapeutics Inc |
3 Q |
- |
-556.99% |
-338.35% |
-104.34% |
Allogene Therapeutics inc |
4 Q |
- |
- |
- |
-44.44% |
Allena Pharmaceuticals Inc. |
2 Q |
- |
- |
- |
-287.46% |
Allovir Inc |
3 Q |
- |
- |
- |
-80.17% |
Ambrx Biopharma Inc |
3 Q |
- |
-43375.47% |
-5666.04% |
-67.63% |
Amgen Inc |
4 Q |
62.03% |
9.36% |
-290.35% |
103.27% |
Apogee Therapeutics inc |
3 Q |
- |
- |
- |
- |
Apeiron Capital Investment Corp |
1 Q |
- |
- |
- |
- |
Aptose Biosciences Inc |
3 Q |
- |
- |
- |
-230.97% |
Argenx se |
4 Q |
96.56% |
-82.9% |
0% |
-25.22% |
Armata Pharmaceuticals Inc |
3 Q |
- |
-2543.76% |
- |
-364.63% |
Athira Pharma Inc |
3 Q |
- |
- |
- |
-61.33% |
Atara Biotherapeutics Inc |
3 Q |
- |
-1270.42% |
- |
-783.31% |
Aura Biosciences Inc |
3 Q |
- |
- |
- |
-40.83% |
Autolus Therapeutics Plc |
3 Q |
- |
- |
- |
-55.3% |
Avrobio Inc |
3 Q |
- |
- |
- |
-4.63% |
Anavex Life Sciences Corp |
4 Q |
- |
-1456.42% |
-1226.18% |
-30.32% |
Axcella Health Inc |
2 Q |
- |
- |
- |
- |
Old Ayala Inc |
4 Q |
0% |
-9131.43% |
-57566.67% |
-308.79% |
Bioatla Inc |
3 Q |
- |
- |
- |
-89.27% |
Biocardia Inc |
3 Q |
- |
-721.01% |
-691.88% |
-645.14% |
Brainstorm Cell Therapeutics inc |
3 Q |
- |
- |
- |
- |
Biocryst Pharmaceuticals Inc |
4 Q |
98.33% |
-66.09% |
-42.87% |
- |
Black Diamond Therapeutics Inc |
4 Q |
- |
- |
- |
-76.43% |
Beam Therapeutics Inc |
3 Q |
- |
-558.88% |
-367.81% |
-40.66% |
Biogen Inc |
4 Q |
74.09% |
10.43% |
-53.89% |
8.08% |
Bluebird Bio Inc |
3 Q |
11.6% |
-578.85% |
1.57% |
-34.32% |
Biontech Se |
4 Q |
- |
- |
- |
51.32% |
Zeo Scientifix Inc |
4 Q |
86.22% |
-90.12% |
-50.61% |
- |
Biondvax Pharmaceuticals Ltd |
4 Q |
- |
- |
- |
-26.72% |
Cabaletta Bio Inc |
3 Q |
- |
- |
- |
-47.05% |
Candel Therapeutics Inc |
3 Q |
- |
- |
- |
-90.47% |
Cannabis Global Inc. |
2 Q |
1.47% |
-59.89% |
-44.25% |
-66.53% |
C4 Therapeutics Inc |
4 Q |
- |
-1065.75% |
- |
-55.3% |
Codiak Biosciences Inc |
3 Q |
- |
-3693.1% |
- |
-37.62% |
Cidara Therapeutics Inc |
3 Q |
- |
-64.26% |
-13.84% |
-238.84% |
Creative Medical Technology Holdings Inc |
3 Q |
60% |
-24232.53% |
- |
-69.54% |
Cullinan Oncology Inc |
3 Q |
- |
- |
- |
-31.5% |
Compugen Ltd |
4 Q |
87% |
-449.25% |
38.76% |
-43.38% |
Cognition Therapeutics inc |
3 Q |
- |
- |
- |
-65.53% |
Coherus Biosciences inc |
4 Q |
7.6% |
-87.03% |
24.73% |
- |
Calidi Biotherapeutics Inc |
4 Q |
- |
- |
- |
- |
Checkmate Pharmaceuticals Inc |
1 Q |
- |
- |
- |
-83.92% |
Compass Therapeutics Inc |
3 Q |
- |
- |
- |
-23.74% |
Coeptis Therapeutics Holdings Inc |
3 Q |
- |
- |
- |
-1692.09% |
Caribou Biosciences Inc |
4 Q |
- |
-969.79% |
-1486.68% |
-31.06% |
Cardiff Oncology inc |
3 Q |
- |
-804.88% |
-342.1% |
-25% |
Cardiol Therapeutics inc |
4 Q |
- |
- |
- |
0% |
Cargo Therapeutics Inc |
3 Q |
- |
- |
- |
- |
Curis Inc |
4 Q |
- |
-434.42% |
82.08% |
-169.22% |
Crispr Therapeutics Ag |
3 Q |
- |
- |
- |
-19.44% |
Clarus Therapeutics Holdings Inc. |
2 Q |
71.36% |
-264.05% |
- |
- |
Champions Oncology Inc |
4 Q |
34.7% |
-21.05% |
-8.69% |
-850.72% |
Cel sci Corporation |
4 Q |
- |
- |
- |
-204.27% |
Cyclo Therapeutics Inc |
4 Q |
72.91% |
-1812.07% |
- |
-4505.67% |
Dbv Technologies S a |
4 Q |
- |
-126.05% |
-87.54% |
-46.36% |
Ginkgo Bioworks Holdings Inc |
3 Q |
98.37% |
-546.44% |
-139.71% |
-56.09% |
Denali Therapeutics Inc |
4 Q |
- |
- |
- |
-0% |
Precision Biosciences Inc |
3 Q |
- |
-61.58% |
-118.62% |
-179.63% |
Dyadic International Inc |
3 Q |
73.34% |
-406.55% |
- |
25770.18% |
Editas Medicine Inc |
4 Q |
- |
-31.43% |
68.47% |
-42.95% |
Eiger Biopharmaceuticals Inc |
3 Q |
96.42% |
-561.86% |
- |
-332.49% |
Elevation Oncology inc |
4 Q |
- |
- |
- |
-81.92% |
Eloxx Pharmaceuticals Inc |
3 Q |
- |
- |
- |
- |
Elutia inc |
4 Q |
13.8% |
-142.63% |
72.88% |
- |
Entera Bio Ltd |
4 Q |
- |
- |
- |
101.78% |
Enzon Pharmaceuticals inc |
3 Q |
- |
51.61% |
-68.33% |
35.29% |
Erytech Pharma S a |
4 Q |
- |
- |
- |
-229.05% |
Estrella Immunopharma Inc |
4 Q |
- |
- |
- |
-117.69% |
Evaxion Biotech A |
4 Q |
- |
- |
- |
-279.04% |
Exelixis Inc |
4 Q |
95.46% |
39.31% |
-27.91% |
19.2% |
Fate Therapeutics Inc |
3 Q |
- |
-2323.56% |
-692.8% |
-38.44% |
4d Molecular Therapeutics Inc |
3 Q |
- |
-50.76% |
- |
-34.73% |
Fennec Pharmaceuticals Inc |
3 Q |
94.92% |
-28.66% |
-39.28% |
- |
Forma Therapeutics Holdings Inc. |
2 Q |
- |
- |
- |
-39.68% |
Finch Therapeutics Group Inc |
3 Q |
- |
- |
- |
-220.02% |
Freeline Therapeutics Holdings Plc |
4 Q |
- |
- |
- |
-267.85% |
Fresh Tracks Therapeutics Inc |
4 Q |
- |
- |
- |
-58.8% |
Fusion Pharmaceuticals Inc |
3 Q |
- |
-860.02% |
-258.47% |
44.47% |
Agentix Corp |
4 Q |
- |
- |
- |
- |
Gilead Sciences Inc |
4 Q |
70.62% |
19.92% |
5.34% |
25.8% |
Monte Rosa Therapeutics Inc |
3 Q |
- |
- |
- |
-58.2% |
Gamida Cell Ltd |
3 Q |
6.98% |
- |
- |
- |
Genocea Biosciences Inc |
1 Q |
- |
-5917.78% |
-6300.37% |
-182.88% |
Genfit S a |
4 Q |
- |
-89.28% |
- |
-25.09% |
Genenta Science S p a |
4 Q |
- |
- |
- |
-27.23% |
Green Planet Bioengineering Co Ltd |
3 Q |
- |
- |
- |
- |
Greenlight Biosciences Holdings Pbc |
1 Q |
- |
-745.26% |
-933.43% |
-374.26% |
Graphite Bio Inc |
3 Q |
- |
- |
- |
-50.5% |
Gritstone Bio Inc |
3 Q |
- |
-2455.85% |
-835.14% |
-57.35% |
Halozyme Therapeutics Inc |
4 Q |
77.27% |
37.12% |
-67.75% |
204.84% |
Hillevax Inc |
3 Q |
- |
- |
- |
-41.96% |
Humacyte Inc |
3 Q |
- |
- |
- |
-120.42% |
Immunitybio inc |
3 Q |
- |
-116636.59% |
- |
- |
Icosavax Inc |
3 Q |
- |
- |
- |
-43.06% |
Ikena Oncology Inc |
3 Q |
- |
-1463.54% |
- |
-42.27% |
Inhibikase Therapeutics Inc |
3 Q |
- |
-5775.11% |
- |
-94.66% |
Immunocore Holdings Plc |
4 Q |
- |
- |
- |
- |
Immunovant Inc |
4 Q |
- |
- |
- |
-61.11% |
In8bio Inc |
3 Q |
- |
- |
- |
-152.8% |
Inhibrx Inc |
4 Q |
- |
-5728.52% |
-3635.43% |
-590.78% |
Mink Therapeutics Inc |
3 Q |
- |
- |
- |
- |
Inmune Bio Inc |
3 Q |
- |
-19913.95% |
-13981.4% |
-52.26% |
Intensity Therapeutics Inc |
3 Q |
- |
- |
- |
- |
Iovance Biotherapeutics Inc |
4 Q |
-805.6% |
-24145.02% |
-31707.88% |
-70.93% |
Innate Pharma Sa |
4 Q |
- |
-100.74% |
- |
-107.3% |
Century Therapeutics inc |
4 Q |
- |
-14700.75% |
-2978.73% |
-58.86% |
Iteos Therapeutics Inc |
3 Q |
- |
- |
- |
-9.72% |
Invivyd Inc |
3 Q |
- |
- |
- |
-56.02% |
Jounce Therapeutics inc |
4 Q |
- |
-0.14% |
89.59% |
-0.08% |
Jasper Therapeutics Inc |
3 Q |
- |
- |
- |
-66.86% |
Kodiak Sciences Inc |
3 Q |
- |
- |
- |
-73.87% |
Kiromic Biopharma Inc |
3 Q |
- |
- |
- |
- |
Krystal Biotech Inc |
4 Q |
- |
20.63% |
-35.39% |
1.63% |
Kymera Therapeutics Inc |
1 Q |
- |
-381.25% |
-148.07% |
-28.51% |
Ladrx Corporation |
3 Q |
- |
- |
- |
- |
Lineage Cell Therapeutics Inc |
3 Q |
86.44% |
-574.48% |
- |
-33.17% |
Semper Paratus Acquisition Corporation |
3 Q |
- |
- |
- |
- |
Atyr Pharma Inc |
3 Q |
- |
-3213.03% |
-706.52% |
-44.81% |
La Jolla Pharmaceutical Company |
2 Q |
83.96% |
23.31% |
39.54% |
- |
Logicbio Therapeutics Inc |
3 Q |
- |
-212.55% |
-296.87% |
-115.29% |
Lexeo Therapeutics Inc |
3 Q |
- |
- |
- |
- |
Mesoblast Ltd |
2 Q |
- |
-1091.71% |
- |
-16.32% |
Meiragtx Holdings Plc |
4 Q |
- |
- |
- |
-75.73% |
Miromatrix Medical inc |
3 Q |
-1018.47% |
-57745.98% |
- |
-140.89% |
Molecular Partners Ag |
4 Q |
- |
-880.7% |
- |
-35.13% |
Moderna Inc |
4 Q |
66.95% |
7.72% |
-0.89% |
-29.87% |
Mymetics Corporation |
3 Q |
- |
-3276.47% |
-1000% |
- |
Neurocrine Biosciences Inc |
4 Q |
98.35% |
28.67% |
-8.27% |
12.85% |
Nkgen Biotech Inc |
3 Q |
- |
- |
- |
- |
Neumora Therapeutics Inc |
3 Q |
- |
- |
- |
- |
Nanostring Technologies Inc |
3 Q |
36.19% |
-77.8% |
-43.32% |
- |
Novavax inc |
4 Q |
46.81% |
-61.23% |
-28.34% |
- |
Ocugen Inc |
3 Q |
- |
- |
- |
-104.7% |
Omega Therapeutics Inc |
3 Q |
- |
-2677.26% |
-2860.29% |
-107.79% |
Organovo Holdings Inc |
3 Q |
- |
- |
- |
-129.61% |
Opthea Limited |
2 Q |
- |
-131469.74% |
- |
- |
Orchard Therapeutics Plc |
3 Q |
72.31% |
-560.44% |
-234.91% |
-74.94% |
Outlook Therapeutics Inc |
4 Q |
- |
- |
- |
- |
Oyster Point Pharma Inc |
3 Q |
75.89% |
-657.25% |
-646.34% |
-652.98% |
Palisade Bio Inc |
3 Q |
- |
- |
- |
-95.08% |
Passage Bio inc |
4 Q |
- |
- |
- |
-73.12% |
Phoenix Biotech Acquisition Corp |
3 Q |
- |
- |
- |
- |
Point Of Care Nano technology Inc |
1 Q |
- |
- |
- |
- |
Vaxcyte Inc |
3 Q |
- |
- |
- |
-25.31% |
Biomx Inc |
3 Q |
- |
- |
- |
173.61% |
Peak Bio Inc |
2 Q |
- |
- |
- |
- |
Pluri Inc |
4 Q |
- |
-4756.19% |
- |
-181.71% |
Protalix Biotherapeutics inc |
4 Q |
15.54% |
-57.64% |
30.76% |
29.73% |
Pharmacyte Biotech Inc |
4 Q |
- |
- |
- |
-5.46% |
Prime Medicine Inc |
4 Q |
- |
- |
- |
0.13% |
Prokidney Corp |
3 Q |
- |
- |
- |
- |
Poseida Therapeutics Inc |
3 Q |
- |
-339.8% |
-260.99% |
-87.41% |
Polarityte Inc |
4 Q |
- |
- |
- |
-43.88% |
Mosaic Immunoengineering Inc |
3 Q |
- |
- |
- |
- |
Qiagen N v |
4 Q |
64.91% |
17.96% |
14.86% |
8.96% |
Qrons Inc |
3 Q |
- |
- |
- |
- |
Renovacor Inc |
3 Q |
- |
- |
- |
-7.46% |
Replicel Life Sciences Inc |
4 Q |
- |
- |
- |
- |
Replimune Group Inc |
4 Q |
- |
- |
- |
-42.94% |
Repligen Corp |
3 Q |
25.89% |
12.87% |
19.21% |
5.93% |
Regenxbio Inc |
3 Q |
57.16% |
-213.97% |
-53.8% |
-59.54% |
Relay Therapeutics Inc |
3 Q |
- |
-260.83% |
21.53% |
-38.24% |
Rubius Therapeutics Inc |
4 Q |
- |
- |
- |
-254.93% |
Revolution Medicines Inc |
3 Q |
- |
- |
- |
-38.92% |
Redwoods Acquisition Corp |
3 Q |
- |
- |
- |
- |
Recursion Pharmaceuticals Inc |
4 Q |
9.28% |
-853.88% |
38.73% |
-72.88% |
Sab Biotherapeutics Inc |
3 Q |
- |
-402.59% |
-422.06% |
-120.36% |
Sana Biotechnology Inc |
3 Q |
- |
- |
- |
-65.36% |
Scilex Holding Company |
3 Q |
66.47% |
-351.18% |
-327.63% |
- |
Seagen Inc |
3 Q |
74.52% |
-33.27% |
18.48% |
-28.06% |
Sangamo Therapeutics Inc |
4 Q |
- |
-2952.74% |
-553.87% |
-131.03% |
Solid Biosciences Inc |
3 Q |
- |
- |
- |
-51.64% |
Senti Biosciences Inc |
3 Q |
- |
-4415.09% |
-4484.91% |
-78.17% |
Sophia Genetics Sa |
4 Q |
69.31% |
-127.57% |
- |
-52.15% |
Spk Acquisition Corp |
3 Q |
-55.59% |
-77.82% |
-8.14% |
- |
Sqz Biotechnologies Company |
3 Q |
- |
- |
- |
0% |
Sorrento Therapeutics Inc |
2 Q |
56.31% |
-722.37% |
- |
- |
Scholar Rock Holding Corp |
3 Q |
- |
- |
- |
-74% |
Surrozen Inc |
3 Q |
- |
- |
- |
-58.26% |
Sutro Biopharma Inc |
3 Q |
- |
-291.21% |
-905.58% |
-103.03% |
Surface Oncology Inc |
2 Q |
- |
- |
- |
-111.71% |
Springworks Therapeutics Inc |
4 Q |
92.25% |
-5968.5% |
- |
-70.33% |
Protara Therapeutics Inc |
3 Q |
- |
- |
- |
-77.06% |
Tarsus Pharmaceuticals Inc |
4 Q |
90.7% |
-320.45% |
-13.19% |
-74.28% |
Tc Biopharm holdings Plc |
4 Q |
- |
-36.15% |
0% |
- |
Tracon Pharmaceuticals Inc |
3 Q |
- |
- |
- |
- |
Tcr2 Therapeutics Inc |
1 Q |
- |
- |
- |
-97.81% |
Tscan Therapeutics Inc |
3 Q |
- |
-591.64% |
-1380.22% |
-65.79% |
Bio techne Corp |
4 Q |
64.78% |
10.08% |
-6.8% |
11.47% |
Instil Bio Inc |
3 Q |
- |
- |
- |
-65.38% |
Tenaya Therapeutics Inc |
3 Q |
- |
- |
- |
-62.76% |
Tourmaline Bio Inc |
3 Q |
- |
- |
- |
-39.66% |
Turnstone Biologics Corp |
3 Q |
- |
- |
- |
- |
Taysha Gene Therapies Inc |
3 Q |
- |
-2467.07% |
- |
- |
Titan Pharmaceuticals Inc |
3 Q |
- |
-19.47% |
- |
-302.58% |
Twist Bioscience Corporation |
4 Q |
40.51% |
-60.15% |
-28.2% |
-31.97% |
Valneva Se |
4 Q |
10.2% |
-39.66% |
95.95% |
-33.41% |
Vericel Corporation |
4 Q |
74.63% |
19.99% |
5.08% |
-1.55% |
10x Capital Venture Acquisition Corp Iii |
3 Q |
- |
- |
- |
- |
Vectivbio Holding Ag |
4 Q |
- |
-342.84% |
- |
-43.93% |
Vigil Neuroscience Inc |
3 Q |
- |
- |
- |
-48.56% |
Vir Biotechnology Inc |
4 Q |
95.25% |
-690.85% |
-1257.27% |
-34.92% |
Vor Biopharma Inc |
3 Q |
- |
- |
- |
-53.72% |
Vaxart Inc |
4 Q |
- |
-535.44% |
46.75% |
-108.45% |
Voyager Therapeutics Inc |
4 Q |
- |
62.62% |
3.92% |
63.89% |
Windtree Therapeutics Inc |
3 Q |
- |
- |
- |
-274.89% |
X4 Pharmaceuticals Inc |
3 Q |
- |
- |
- |
-170.43% |
Xtant Medical Holdings Inc |
3 Q |
63.01% |
37.93% |
17.67% |
7.22% |
Zivo Bioscience Inc |
4 Q |
35.01% |
-16174.14% |
-10256.47% |
- |
Zura Bio Limited |
3 Q |
- |
- |
- |
-155.26% |